Search
Thyrotropin alfa
go.drugbank.com/drugs/DB00024ApprovedInvestigationalVet approvedThe beta subunit (TSHB) bestows its receptor specificity due to the uniqueness to TSH. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone. … The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic
Categories: Agents used to treat hypothyroidismAndexanet alfa
go.drugbank.com/drugs/DB14562ApprovedThe amino acid residue modification from serine to alanine in the binding site of the catalytic domain allows more effective binding to FXa inhibitors and deters the andexanet alfa from converting prothrombin … to thrombin [A35558].
Nitrous oxide
go.drugbank.com/drugs/DB06690ApprovedInvestigationalVet approvedIt is known as "laughing gas" due to the euphoric effects of inhaling it, a property that has led to its recreational use as an inhalant drug. … Nitrous oxide, commonly known as "laughing gas", is a chemical compound with the chemical formula N2O.
Mixtures: OXICALM® MEZCLA MEDICINAL DE OXIGENO: OXIDO NITROSOAnethole trithione
go.drugbank.com/drugs/DB13853ApprovedAnethole trithione (ATT) appears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia [A27165, A32618, A32620, A32621], to demonstrating an ability to … Unfortunately, many of the specific mechanisms of action to these activities have yet to be formally elucidated, which means that while studies are ongoing, ATT itself is not necessarily formally indicated
Stem bromelain
go.drugbank.com/drugs/DB12249ApprovedThe primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the … This action allows bromelain to demonstrate a wide range of therapeutic benefits ranging from cardiovascular to anticancer therapy - but the specific mechanisms of action by which it can elicit these effects
Rabies immune globulin, human
go.drugbank.com/drugs/DB11603ApprovedIf IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies … Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory
Andusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigational[elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant. … Andusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g.
Abacavir
go.drugbank.com/drugs/DB01048ApprovedInvestigationalChemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. … In vivo, abacavir sulfate dissociates to its free base, abacavir.
Mixtures: ABACAVIR E LAMIVUDINA LUPIN, ABACAVIR E LAMIVUDINA LUPINCategories: Antivirals used in combination for the treatment of HIV infectionsIndapamide
go.drugbank.com/drugs/DB00808ApprovedInvestigationalThe most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. … agents may be required in order to achieve blood pressure targets.
Mixtures: PERINDO/IN RAT T 5/1.25, PERINDO/IN RAT T 5/1.25Products: COMPRIMIDOS RECUBIERTOS DE LIBERACION PROLONGADA, INDAPAMIDA 1.5 MG TABLETA DE LIBERACION PROLONGADAGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[L52680,L52685] In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. [L54803] … [A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.